玻璃体腔注射贝伐珠单抗治疗糖尿病黄斑水肿后中央脉络膜厚度变化与中央黄斑厚度及最佳矫正视力的相关性
这项前瞻性干预性病例系列纳入20例中心受累型糖尿病黄斑水肿初治患者(20眼),每月玻璃体腔注射贝伐珠单抗共3次。基线平均中央脉络膜厚度265±79μm,第3个月和第6个月分别降至251±81μm和232±82μm(P<0.001);中央黄斑厚度相应从470±107μm降至392±104μm和324±122μm(P<0.001);最佳矫正视力从基线20/60改善至第3个月20/50和第6个月20/40(P=0.007)。中央脉络膜厚度每减少1μm,与中央黄斑厚度减少2.74μm及最佳矫正视力提高0.1个早期治疗糖尿病视网膜病变研究字母评分相关(P<0.001和P=0.001)。
要点
- 中央脉络膜厚度每减少1μm,中央黄斑厚度减少2.74μm(P<0.001)。
- 中央脉络膜厚度每减少1μm,最佳矫正视力提高0.1个ETDRS字母评分(P=0.001)。
核心结论
- 玻璃体腔注射贝伐珠单抗治疗糖尿病黄斑水肿后中央脉络膜厚度降低,且该降低与中央黄斑厚度降低和视力改善显著相关。
研究设计与样本
- 前瞻性干预性病例系列,纳入20例中心受累型糖尿病黄斑水肿初治患者的20眼,每月玻璃体腔注射贝伐珠单抗共3次,于第1、2、3、6个月随访。
主要发现
- 患者平均年龄63.1±8.0岁(范围52-75岁)。
- 平均中央脉络膜厚度从基线265±79μm降至第3个月251±81μm和第6个月232±82μm(P<0.001)。
- 平均中央黄斑厚度从基线470±107μm降至第3个月392±104μm和第6个月324±122μm(P<0.001)。
- 最佳矫正视力从基线20/60改善至第3个月20/50和第6个月20/40(P=0.007)。
关键数值与推荐
- 中央脉络膜厚度每减少1μm,与中央黄斑厚度减少2.74μm相关(P<0.001)。
- 中央脉络膜厚度每减少1μm,与最佳矫正视力提高0.1个早期治疗糖尿病视网膜病变研究字母评分相关(P=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the effect of intravitreal injection of bevacizumab on central choroidal thickness (CCT) and its relationship with central macular thickness (CMT) and best-corrected visual acuity (BCVA) changes in eyes with center-involving diabetic macular edema. METHODS: This prospective interventional case series included 20 eyes of 20 patients with center-involving diabetic macular edema naive to treatment. The BCVA assessment, complete eye examination, enhanced depth optical coherence tomography, and fluorescein angiography were performed at baseline followed by 3 monthly intravitreal injection of bevacizumab. The treated eyes underwent BCVA evaluation and enhanced depth optical coherence tomography at Months 1, 2, 3, and 6 after the first injection. Change of the CCT was the primary outcome measure. Secondary outcome measures included BCVA and CMT changes and their relationship with CCT changes. RESULTS: Mean age of patients was 63.1 ± 8.0 (range, 52-75) years. Mean baseline CCT was 265 ± 79 μm, which reduced to 251 ± 81 μm and 232 ± 82 μm at Months 3 and 6, respectively (P < 0.001). Corresponding values for CMT were 470 ± 107 μm, 392 ± 104 μm, and 324 ± 122 μm, respectively (P < 0.001). The BCVA improved from 20/60 at baseline to 20/50 at Month 3 and 20/40 at Month 6 (P = 0.007). Each 1 μm decrease in CCT was associated with 2.74 μm reduction in CMT and 0.1 Early Treatment Diabetic Retinopathy Study letter score improvement in BCVA (P < 0.001 and P = 0.001, respectively). CONCLUSION: After treatment of diabetic macular edema with intravitreal injection of bevacizumab, CCT decreased and this reduction significantly correlated with CMT reduction and vision improvement.
引用
- Nourinia R, Ahmadieh H, Nekoei E, et al. CHANGES IN CENTRAL CHOROIDAL THICKNESS AFTER TREATMENT OF DIABETIC MACULAR EDEMA WITH INTRAVITREAL BEVACIZUMAB CORRELATION WITH CENTRAL MACULAR THICKNESS AND BEST-CORRECTED VISUAL ACUITY. Retina. 2018. PMID: 28426622. doi:10.1097/IAE.0000000000001645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。